In 2023, Merck & Co. spent more than half of its revenue on R&D. Sure, the figure was inflated thanks to its $10.8 billion acquisition of Prometheus Biosciences, which it budgeted as an R&D cost. But Moderna spent even more as a percentage, $4.85 billion of its $6.85 billion revenue in revenue on R&D while…